![Regina Salvat](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Regina Salvat
Direttore/Membro del Consiglio presso Pionyr Immunotherapeutics, Inc.
Profilo
Regina Salvat is currently the Director at Pionyr Immunotherapeutics, Inc. and the Principal at Sofinnova Investments, Inc. She completed her undergraduate degree at Cornell University in 1990 and holds a doctorate degree from Thayer School of Engineering At Dartmouth.
Posizioni attive di Regina Salvat
Società | Posizione | Inizio |
---|---|---|
Sofinnova Investments, Inc.
![]() Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | Analista di Private Equity | 01/06/2020 |
Pionyr Immunotherapeutics, Inc.
![]() Pionyr Immunotherapeutics, Inc. BiotechnologyHealth Technology Pionyr Immunotherapeutics, Inc. develops cancer immunotherapies. It targets the tumor microenvironment to enhance the body?s antitumor immunity. The company was founded by Max Krummel and Sachdev Sidhu in 2015 and is headquartered in San Francisco, CA. | Direttore/Membro del Consiglio | - |
Formazione di Regina Salvat
Cornell University | Undergraduate Degree |
Thayer School of Engineering At Dartmouth | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 2 |
---|---|
Sofinnova Investments, Inc.
![]() Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | Finance |
Pionyr Immunotherapeutics, Inc.
![]() Pionyr Immunotherapeutics, Inc. BiotechnologyHealth Technology Pionyr Immunotherapeutics, Inc. develops cancer immunotherapies. It targets the tumor microenvironment to enhance the body?s antitumor immunity. The company was founded by Max Krummel and Sachdev Sidhu in 2015 and is headquartered in San Francisco, CA. | Health Technology |
- Borsa valori
- Insiders
- Regina Salvat